サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1362868

呼吸器合胞体ウイルス診断の市場規模、シェア、動向分析レポート：製品別、最終用途別、地域別、セグメント予測、2023年～2030年

Respiratory Syncytial Virus Diagnostics Market Size, Share & Trends Analysis Report By Product (DFA, RADT, Molecular Diagnostics, Chromatographic Immunoassay), By End-use, By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 118 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
呼吸器合胞体ウイルス診断の市場規模、シェア、動向分析レポート：製品別、最終用途別、地域別、セグメント予測、2023年～2030年
出版日: 2023年09月01日
発行: Grand View Research
ページ情報: 英文 118 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

呼吸器合胞体ウイルス診断市場の成長と動向：

Grand View Research, Inc.の新しい調査によると、世界の呼吸器合胞体ウイルス診断市場は、2023年から2030年まで推定CAGR 9.7%で成長し、2030年までに19億4,730万米ドルに達すると予測されています。

RSV感染症を含む呼吸器疾患に罹患する新生児人口の増加と、医療提供者による新生児診断のための支援イニシアチブは、RSV診断市場の重要な影響促進要因になると予想されます。

WHOの統計によると、米国では2014年に15万人以上の小児（5歳未満）がRSV感染症で入院し、約1万4000人の老年患者が死亡しました。このことは、予測期間中、これらの疾患の検査需要を誘発すると予想されます。

さらに、2014年現在の世界の出生率は1,000人当たり18.7人であり、今後7年間で乳幼児人口が大幅に増加すると予測されています。統計によると、2014年には約1億3,420万人の出産があったと推定され、これらの出産はRSV感染症にかかりやすく、診断が必要であるため、大きな市場基盤を形成しています。

2010年、Save Babies Through Screening Foundation（SBTS）はWorld Solutions Against Infectious Disease（WSAID）とパートナーシップを結び、新生児の感染症、代謝障害、聴覚障害のスクリーニングを推進する試みを開始しました。

呼吸器合胞体ウイルス診断市場レポートハイライト

  • クロマトグラフィー免疫測定技術をベースとした製品は、分子診断製品よりも特異性が高いため、今後7年間のCAGRが10.0%を超え、最も速い成長が見込まれます。市販の検査キットには、Binax Now RSV、QuickLab RSV Test、Remel Xpect、RSV Respi-Stripなどがあります。
  • 病院がRSV診断市場を独占すると予測され、次いで在宅医療が続く。両者を合わせると、2022年には市場シェアの50.0%以上を占めると予測されます。患者による在宅医療診断機器への需要の増加が、今後7年間の同分野の成長を牽引すると予測されます。
  • 北米が市場を独占し、2022年までに41.5％以上の売上高シェアを占めると予測されます。新生児スクリーニングを開始・実施するための住民の意識の高まりや、WHO、PAHO、WSAIDなどの政府機関による好意的な取り組みが成長を促進すると予想されます。
  • 同市場の主要企業には、Alere Inc.、EMD Millipore、BD and Company、Ortho Clinical Diagnostics、Roche Diagnostics、Abbott Laboratories、Thermo Fisher Scientific Inc.などがあります。Roche Diagnostics、Becton Dickinson and Company、Alere Inc.などの企業によるCLIAの認可やRSVアッセイの発売は、予測期間中の市場成長を後押しすると期待されています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 呼吸器合胞体ウイルス（RSV）診断市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因分析
  • 呼吸器合胞体ウイルス（RSV）診断市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 呼吸器合胞体ウイルス（RSV）診断市場：製品推定・動向分析

  • 呼吸器合胞体ウイルス（RSV）診断市場：重要なポイント
  • 呼吸器合胞体ウイルス（RSV）診断市場：動向と市場シェア分析、2022年および2030年
  • 直接蛍光抗体（DFA）法
  • 迅速抗原診断検査（RADT）
  • 分子診断学
  • クロマトグラフィーイムノアッセイ
  • 画像診断
  • ゲル微小液滴
  • フローサイトメトリー
  • その他

第5章 呼吸器合胞体ウイルス（RSV）診断市場：最終使用推定・動向分析

  • 呼吸器合胞体ウイルス（RSV）診断市場：重要なポイント
  • 呼吸器合胞体ウイルス（RSV）診断市場：動向と市場シェア分析、2022年および2030年
  • 病院
  • 研究室
  • クリニック
  • ホームケア

第6章 呼吸器合胞体ウイルス（RSV）診断市場：地域推定・動向分析

  • 地域別の展望
  • 地域別呼吸器合胞体ウイルス（RSV）診断市場：主要なマーケットプレースのポイント
  • 北米
    • 市場推計・予測、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 市場参入企業の分類
    • Becton, Dickinson and Company
    • Novartis AG
    • Abbott
    • Ortho Clinical Diagnostics
    • Thermo Fisher Scientific Inc.
    • Bio-Rad Laboratories, Inc.
    • F. Hoffmann-La Roche Ltd
    • BIOMERIEUX
    • DiaSorin S.p.A.
    • Merck KGaA
    • Quidel Corporation
    • Coris BioConcept
    • Quest Diagnostics
    • Siemens Healthcare S.A.
図表

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 3 North America respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 4 North America respiratory syncytial virus diagnostic market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 6 U.S. respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 7 Canada respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 8 Canada respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 9 Europe respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 10 Europe respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 11 Europe respiratory syncytial virus diagnostic market, by region, 2018 - 2030 (USD Million)
  • Table 12 UK respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 13 UK respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 14 Germany respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 15 Germany respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 16 France respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 17 France respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 18 Italy respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 19 Italy respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 20 Spain respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 21 Spain respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 22 Denmark respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 23 Denmark respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 24 Sweden respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 25 Sweden respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 26 Norway respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 27 Norway respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific respiratory syncytial virus diagnostic market, by region, (USD Million) 2018 - 2030
  • Table 31 Japan respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 32 Japan respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 33 China respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 34 China respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 35 India respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 36 India respiratory syncytial virus diagnostic market, by end-use, (USD Million) 2018 - 2030
  • Table 37 Australia respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 38 Australia respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 39 Thailand respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 40 Thailand respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 41 South Korea respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 42 South Korea respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 43 Latin America respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 44 Latin America respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 45 Latin America respiratory syncytial virus diagnostic market, by region, 2018 - 2030 (USD Million)
  • Table 46 Brazil respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 47 Brazil respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 48 Mexico respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 49 Mexico respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 Argentina respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 51 Argentina respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 53 Middle East and Africa respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 54 Middle East and Africa respiratory syncytial virus diagnostic market, by region, 2018 - 2030 (USD Million)
  • Table 55 South Africa respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 56 South Africa respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 59 UAE respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 60 UAE respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 61 Kuwait respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 62 Kuwait respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Respiratory syncytial virus diagnostic: Market outlook
  • Fig. 9 Respiratory syncytial virus diagnostic: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Respiratory syncytial virus diagnostic market driver impact
  • Fig. 15 Respiratory syncytial virus diagnostic market restraint impact
  • Fig. 16 Respiratory syncytial virus diagnostic market strategic initiatives analysis
  • Fig. 17 Respiratory syncytial virus diagnostic market: Product movement analysis
  • Fig. 18 Respiratory syncytial virus diagnostic market: product outlook and key takeaways
  • Fig. 19 Direct fluorescent antibody (DFA) method market estimates and forecasts, 2018 - 2030
  • Fig. 20 Rapid antigen diagnostic test (RADT) market estimates and forecasts, 2018 - 2030
  • Fig. 21 Molecular diagnostic market estimates and forecasts, 2018 - 2030
  • Fig. 22 Chromatographic immunoassay market estimates and forecasts, 2018 - 2030
  • Fig. 23 Diagnostic imaging market estimates and forecasts, 2018 - 2030
  • Fig. 24 Gel microdroplets immunoassay market estimates and forecasts, 2018 - 2030
  • Fig. 25 Flow cytometry immunoassay market estimates and forecasts, 2018 - 2030
  • Fig. 26 Others market estimates and forecasts, 2018 - 2030
  • Fig. 27 Respiratory syncytial virus diagnostic market: End-use movement analysis
  • Fig. 28 Respiratory syncytial virus diagnostic market: End-use outlook and key takeaways
  • Fig. 29 Hospital market estimates and forecasts, 2018 - 2030
  • Fig. 30 Laboratory market estimates and forecasts, 2018 - 2030
  • Fig. 31 Clinics market estimates and forecasts, 2018 - 2030
  • Fig. 32 Homecare market estimates and forecasts, 2018 - 2030
  • Fig. 33 Global respiratory syncytial virus diagnostic market: Regional movement analysis
  • Fig. 34 Global respiratory syncytial virus diagnostic market: Regional outlook and key takeaways
  • Fig. 35 North America market estimates and forecasts, 2018 - 2030
  • Fig. 36 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 37 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 38 Europe. market estimates and forecasts, 2018 - 2030
  • Fig. 39 UK market estimates and forecasts, 2018 - 2030
  • Fig. 40 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 41 France market estimates and forecasts, 2018 - 2030
  • Fig. 42 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 43 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 44 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 45 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 46 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 47 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 48 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 49 China market estimates and forecasts, 2018 - 2030
  • Fig. 50 India market estimates and forecasts, 2018 - 2030
  • Fig. 51 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 52 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 53 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 54 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 55 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 56 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 57 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 58 Middle East and Africa. market estimates and forecasts, 2018 - 2030
  • Fig. 59 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 60 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 61 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 62 Kuwait market estimates and forecasts, 2018 - 2030
目次
Product Code: 978-1-68038-680-6

Respiratory Syncytial Virus Diagnostics Market Growth & Trends:

The global respiratory syncytial virus diagnostics market is expected to reach USD 1947.3 million by 2030, growing at an estimated CAGR of 9.7% from 2023 to 2030, according to a new study by Grand View Research, Inc.. Increasing neonatal population suffering from respiratory conditions including RSV infections and supportive initiatives for diagnosis of newborns by the healthcare providers are expected to be vital impact rendering drivers for RSV diagnostics market.

According to the statistics provided by the WHO, hospitalization of over 150,000 children (below the age of five) and about 14,000 deaths in geriatric patients occurred in the U.S. in 2014 due to RSV infections. This is anticipated to trigger demand for testing of these conditions over the forecast period.

Furthermore, the global birth rate as of 2014 is 18.7 births per 1,000 individuals, which is predicted to increase the infant population substantially over the next seven years. According to the statistics, it is estimated that about 134.2 million births took place in 2014, which are prone to RSV infections and require diagnosis, thus forming a large market base.

In 2010, Save Babies Through Screening Foundation (SBTS) entered in a partnership with World Solutions Against Infectious Disease (WSAID) as an attempt to promote higher screening of newborns for infectious diseases, metabolic disorders, and hearing disabilities.

Respiratory Syncytial Virus Diagnostics Market Report Highlights:

  • Chromatographic immunoassay technology based products are expected to witness the fastest growth at a CAGR above 10.0% over the next seven years owing to their higher specificity than molecular diagnostic products. The commercially available test kits include Binax Now RSV, QuickLab RSV Test, Remel Xpect, and RSV Respi-Strip.
  • Hospitals are predicted to dominate the RSV diagnostics market followed by home care. Together, they are expected to contribute over 50.0% of the market share in 2022. Increasing demand for home care diagnostic devices by patients is anticipated to drive growth of the segment over the next seven years.
  • North America is anticipated to dominate the market and contribute a revenue share of over 41.5% by 2022. Rising awareness among the population base and favorable initiatives by the government agencies such as the WHO, PAHO, and WSAID to initiate and implement newborn screening are expected to drive growth.
  • Key players of the market include Alere Inc., EMD Millipore, BD and Company, Ortho Clinical Diagnostics, Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific Inc. CLIA waiver and launch of RSV assays by companies like Roche Diagnostics, Becton Dickinson and Company, and Alere Inc. are expected to boost market growth over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. End-use
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. End-use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Respiratory Syncytial Virus (RSV) Diagnostic Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Respiratory Syncytial Virus (RSV) Diagnostic Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Respiratory Syncytial Virus (RSV) Diagnostic Market: Product Estimates & Trend Analysis

  • 4.1. Respiratory Syncytial Virus (RSV) Diagnostic Market: Key Takeaways
  • 4.2. Respiratory Syncytial Virus (RSV) Diagnostic Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Direct Fluorescent Antibody (DFA) Method
    • 4.3.1. Direct fluorescent antibody (DFA) Method estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Rapid Antigen Diagnostic Test (RADT)
    • 4.4.1. Rapid Antigen Diagnostic Test (RADT) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Molecular Diagnostics
    • 4.5.1. Molecular diagnostic market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Chromatographic Immunoassay
    • 4.6.1. Chromatographic immunoassay market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Diagnostic Imaging
    • 4.7.1. Diagnostic imaging Immunoassay market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8. Gel Microdroplets
    • 4.8.1. Gel microdroplets imaging immunoassay market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.9. Flow Cytometry
    • 4.9.1. Flow cytometry imaging immunoassay market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Respiratory Syncytial Virus (RSV) Diagnostic Market: End-use Estimates & Trend Analysis

  • 5.1. Respiratory Syncytial Virus (RSV) Diagnostic Market: Key Takeaways
  • 5.2. Respiratory Syncytial Virus (RSV) Diagnostic Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Hospitals
    • 5.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Laboratory
    • 5.4.1. Laboratory market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Clinics
    • 5.5.1. Clinics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Homecare
    • 5.6.1. Homecare market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Respiratory Syncytial Virus (RSV) Diagnostic Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Respiratory Syncytial Virus (RSV) Diagnostic Market by Region: Key Marketplace Takeaway
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Denmark
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Norway
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Becton, Dickinson and Company
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Novartis AG
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Abbott
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Ortho Clinical Diagnostics
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Thermo Fisher Scientific Inc.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Bio-Rad Laboratories, Inc.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. F. Hoffmann-La Roche Ltd
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. BIOMERIEUX
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. DiaSorin S.p.A.
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. Merck KGaA
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
    • 7.2.11. Quidel Corporation
      • 7.2.11.1. Company overview
      • 7.2.11.2. Financial performance
      • 7.2.11.3. Product benchmarking
      • 7.2.11.4. Strategic initiatives
    • 7.2.12. Coris BioConcept
      • 7.2.12.1. Company overview
      • 7.2.12.2. Financial performance
      • 7.2.12.3. Product benchmarking
      • 7.2.12.4. Strategic initiatives
    • 7.2.13. Quest Diagnostics
      • 7.2.13.1. Company overview
      • 7.2.13.2. Financial performance
      • 7.2.13.3. Product benchmarking
      • 7.2.13.4. Strategic initiatives
    • 7.2.14. Siemens Healthcare S.A.
      • 7.2.14.1. Company overview
      • 7.2.14.2. Financial performance
      • 7.2.14.3. Product benchmarking
      • 7.2.14.4. Strategic initiatives